Home » Topics » Regulatory » EMA

EMA
RSS

EMA accepts cemiplimab MAA for cutaneous squamous cell carcinoma

April 3, 2018

Lanadelumab submissions in E.U. and Canada accepted for review

March 29, 2018

EMA accepts BioMarin's MAA for pegvaliase to treat adults with PKU

March 29, 2018

EMA validates application for Cabometyx for previously treated advanced HCC

March 28, 2018

EMA committee recommends approval of new dosing schedules for Opdivo in E.U.

March 27, 2018

EMA grants PRIME designation for lumasiran in primary hyperoxaluria type 1

March 27, 2018

CHMP supports conditional marketing authorization for Clovis Oncology's Rubraca

March 26, 2018

Amgen, Allergan receive positive opinion in E.U. for ABP-980

March 26, 2018

EMA recommends including new indication in Repatha label

March 26, 2018

EMA committee issues negative opinion on Portola's betrixaban

March 26, 2018

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...